-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $27, 'We view this as Novo taking a direct shot at HIMS'
-
Novo Nordisk (NVO) Completes $16.5B Acquisition of Catalent
-
Catalent (CTLT) and Novo Holdings (NVO) Receive European Commission Unconditional Approval for Pending Transaction
-
Novo Nordisk added to Citi's Europe 1 list of top ideas
-
Citi Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Citi Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Buy the dip in this major pharma stock - Citi
-
Midday movers: Tesla, Coinbase rise; Uber falls
-
Citi - Introducing Europe’s 'Super 7'
-
Catalent (CTLT) Acquired by Novo Holdings (NVO) in $16.5B Deal
-
DaVita, Fresenius Medical Care, Baxter crushed as Ozempic effective in kidney trial
-
Citi Reiterates Buy Rating on Novo Nordisk (NVO)
-
Citi Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Buy
-
Citi Reiterates Neutral Rating on Novo Nordisk (NVO), Open Negative Catalyst Watch
-
Lilly's diabetes drug data impresses, hurts rival Novo's shares
-
Citi Downgrades Novo Nordisk (NVO) to Neutral
-
Notable Analyst Rating Changes 03/18: (ODP) (VZ) (GLUU) Upgraded; (NVO) (CCL) (CNP) Downgraded
-
Citi Upgrades Novo Nordisk (NVO) to Buy
-
Citi Upgrades Novo Nordisk (NVO) to Buy
-
Notable Analyst Rating Changes 4/6: WYNN, JOYG, BUCY, TWC, NVO Upgraded; CSCO, ICE, ABT, VIA, BHP, RTP Downgraded
-
Morning Movers 3/26: CTRN, CONN, BBY, GM, RHT, DPS Higher; UTIW, MFE, SNDA Lower
-
Citi Downgrades Novo Nordisk (NVO) to Sell

